Ligorio, F., Fucà, G., Zattarin, E., Lobefaro, R., Zambelli, L., Leporati, R., . . . Vernieri, C. (2021). The Pan-Immune-Inflammation-Value Predicts the Survival of Patients with Human Epidermal Growth Factor Receptor 2 (HER2)—Positive Advanced Breast Cancer Treated with First-Line Taxane-Trastuzumab-Pertuzumab. Cancers (Basel).
Styl ChicagoLigorio, Francesca, et al. "The Pan-Immune-Inflammation-Value Predicts the Survival of Patients With Human Epidermal Growth Factor Receptor 2 (HER2)—Positive Advanced Breast Cancer Treated With First-Line Taxane-Trastuzumab-Pertuzumab." Cancers (Basel) 2021.
Citace podle MLALigorio, Francesca, et al. "The Pan-Immune-Inflammation-Value Predicts the Survival of Patients With Human Epidermal Growth Factor Receptor 2 (HER2)—Positive Advanced Breast Cancer Treated With First-Line Taxane-Trastuzumab-Pertuzumab." Cancers (Basel) 2021.